ArticleNature communications2019
FDA-ARGOS is a database with public quality-controlled reference genomes for diagnostic use and regulatory science.
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 331 citations in OpenAlex.
- Phylogenetic distribution and longitudinal persistence of plasmids inMicrobial genomics · 2026Article
- Sudden death with pseudomembranous fibrinonecrotic enteritis in a zoo-housed hippopotamus (Journal of veterinary science · 2026Article
- Medical software for precision diagnostics of infection with immunoprofiling and artificial intelligence.Journal of translational medicine · 2026Review
- A framework of Microbial Genomic Database for clinical metagenomic pathogen diagnosis: development and multi-cohort evaluation.Frontiers in cellular and infection microbiology · 2026Article
- The Kocurious case of Noodlococcus: genomic insights intoMicrobial genomics · 2025Article
- Article
- Article
- Physiology, Heavy Metal Resistance, and Genome Analysis of TwoMicroorganisms · 2025Article
- A framework towards implementation of sequencing for antimicrobial-resistant and other health-care-associated pathogens.The Lancet. Infectious diseases · 2025Review
- Kalamari: a representative set of genomes of public health concern.Microbiology resource announcements · 2025Article
- Incomplete human reference genomes can drive false sex biases and expose patient-identifying information in metagenomic data.Nature communications · 2025Article
- Metagenomics: a new frontier for routine pathology testing of gastrointestinal pathogens.Gut pathogens · 2025Article
- Genomic analysis and potential polyhydroxybutyrate (PHB) production from Bacillus strains isolated from extreme environments in Mexico.BMC microbiology · 2025Article
- A retrospective analysis comparing metagenomic next-generation sequencing with conventional microbiology testing for the identification of pathogens in patients with severe infections.Frontiers in cellular and infection microbiology · 2025Article
- The activity of cell-free supernatant ofFrontiers in cellular and infection microbiology · 2025Article
- Identifying potential novel widespread determinants of bacterial pathogenicity using phylogenetic-based orthology analysis.Frontiers in microbiology · 2025Article
- Enhancing bloodstream infection diagnostics: a novel filtration and targeted next-generation sequencing approach for precise pathogen identification.Frontiers in microbiology · 2025Article
- Article
- Laboratory validation of a clinical metagenomic next-generation sequencing assay for respiratory virus detection and discovery.Nature communications · 2024Article
- Incomplete human reference genomes can drive false sex biases and expose patient-identifying information in metagenomic data.Research square · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 1 country.
Funding
Abstract
FDA proactively invests in tools to support innovation of emerging technologies, such as infectious disease next generation sequencing (ID-NGS). Here, we introduce FDA-ARGOS quality-controlled reference genomes as a public database for diagnostic purposes and demonstrate its utility on the example of two use cases. We provide quality control metrics for the FDA-ARGOS genomic database resource and outline the need for genome quality gap filling in the public domain. In the first use case, we show more accurate microbial identification of Enterococcus avium from metagenomic samples with FDA-ARGOS reference genomes compared to non-curated GenBank genomes. In the second use case, we demonstrate the utility of FDA-ARGOS reference genomes for Ebola virus target sequence comparison as part of a composite validation strategy for ID-NGS diagnostic tests. The use of FDA-ARGOS as an in silico target sequence comparator tool combined with representative clinical testing could reduce the burden for completing ID-NGS clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.